Esperion Therapeutics, Inc.
ESPRDelisted Jul 13, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001434868
Esperion Therapeutics, Inc. was delisted on Jul 13, 2026; its insiders filed their last Form 4 on Jul 13, 2026; 191 institutions reported holding it in 13F filings for Q2 2026, worth $646.8M in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Esperion Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Esperion Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Hoffman Robert | Director | 0 | Jul 13, 2026 | 2 |
| Carroll J Martin | Director | 0 | Jul 13, 2026 | 2 |
| Shepard Jay | Director | 0 | Jul 13, 2026 | 2 |
| Fischer Seth H. Z. | Director | 0 | Jul 13, 2026 | 2 |
| Thompson John Craig | Director | 0 | Jul 13, 2026 | 2 |
| Harlow John B. Jr. | Chief Commercial Officer | 0 | Jul 13, 2026 | 2 |
| Looker Benjamin | Chief Legal Officer | 0 | Jul 13, 2026 | 7 |
| Halladay Benjamin | Chief Financial Officer | 0 | Jul 13, 2026 | 5 |
| Koenig Sheldon L. | President and CEO | 0 | Jul 13, 2026 | 5 |
| Vitullo Nicole | Director | 36,918 | Jun 2, 2025 | 0 |
| Rocamboli Stephen | Director | 69,261 | Jun 2, 2025 | 0 |
| Woody Tracy M | Director | 33,566 | Jun 2, 2025 | 0 |
| Warren Eric | Chief Commercial Officer | 370,218 | Apr 21, 2025 | 0 |
| Foody Joanne M. | Chief Medical Officer | 272,862 | Jul 19, 2024 | 0 |
| Gotto Antonio M Jr MD D Phil | Director | 51,599 | May 24, 2024 | 0 |
| Fuhrman Alan | Director | 53,404 | May 24, 2024 | 0 |
| Berkowitz Jeffrey | Director | – | May 27, 2022 | 0 |
| Bartram Richard | Chief Financial Officer | 82,751 | Mar 16, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2025 (view filing) | Mar 18 | 1 day | Koenig Sheldon L.President and CEO | SSale | −13.0K | $1.50 | −$19.6K | −0.8%1.57M after | |
| Mar 19, 2025 (view filing) | Mar 18 | 1 day | Warren EricChief Commercial Officer | SSale | −2.43K | $1.49 | −$3.63K | −0.7%370.3K after | |
| Mar 19, 2025 (view filing) | Mar 18 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −3.54K | $1.48 | −$5.23K | −0.7%481.7K after | |
| Apr 21, 2025 (view filing) | Apr 17 | 4 days | Halladay BenjaminChief Financial Officer | SSale | −8 | $0.96 | −$7.68 | 0.0%481.7K after | |
| Apr 21, 2025 (view filing) | Apr 17 | 4 days | Warren EricChief Commercial Officer | SSale | −108 | $0.98 | −$105.84 | 0.0%370.2K after | |
| Jun 18, 2025 (view filing) | Jun 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −7.23K | $1.15 | −$8.31K | −1.5%474.5K after | |
| Jun 18, 2025 (view filing) | Jun 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −30.5K | $1.11 | −$33.8K | −1.9%1.54M after | |
| Jun 18, 2025 (view filing) | Jun 17 | 1 day | Looker BenjaminGeneral Counsel | SSale | −6.42K | $1.15 | −$7.39K | −1.6%401.2K after | |
| Jul 18, 2025 (view filing) | Jul 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −11 | $1.12 | −$12.32 | 0.0%474.5K after | |
| Jul 18, 2025 (view filing) | Jul 17 | 1 day | Looker BenjaminGeneral Counsel | SSale | −1.30K | $1.13 | −$1.47K | −0.3%399.9K after | |
| Sep 18, 2025 (view filing) | Sep 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −28.4K | $2.79 | −$79.3K | −1.8%1.52M after | |
| Sep 18, 2025 (view filing) | Sep 17 | 1 day | Looker BenjaminGeneral Counsel | SSale | −6.27K | $2.80 | −$17.5K | −1.6%393.7K after | |
| Sep 18, 2025 (view filing) | Sep 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −7.05K | $2.81 | −$19.8K | −1.5%474.9K after | |
| Oct 20, 2025 (view filing) | Oct 17 | 3 days | Looker BenjaminGeneral Counsel | SSale | −1.25K | $2.62 | −$3.27K | −0.3%392.4K after | |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Looker BenjaminGeneral Counsel | SSale | −6.52K | $3.67 | −$23.9K | −1.7%385.9K after | |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −7.34K | $3.67 | −$26.9K | −1.5%467.5K after | |
| Dec 18, 2025 (view filing) | Dec 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −48.2K | $3.67 | −$177.1K | −3.2%1.47M after | |
| Jan 21, 2026 (view filing) | Jan 20 | 1 day | Looker BenjaminGeneral Counsel | SSale | −1.69K | $2.88 | −$4.86K | −0.4%384.2K after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −6.42K | $2.71 | −$17.4K | −0.9%713.6K after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −25.6K | $2.72 | −$69.6K | −1.2%2.17M after | |
| Mar 18, 2026 (view filing) | Mar 17 | 1 day | Looker BenjaminChief Legal Officer | SSale | −5.71K | $2.70 | −$15.4K | −0.8%679.3K after | |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Halladay BenjaminChief Financial Officer | SSale | −10.8K | $3.16 | −$34.0K | −1.5%702.8K after | |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Koenig Sheldon L.President and CEO | SSale | −53.6K | $3.16 | −$169.3K | −2.5%2.12M after | |
| Jun 18, 2026 (view filing) | Jun 17 | 1 day | Looker BenjaminChief Legal Officer | SSale | −11.8K | $3.16 | −$37.4K | −1.7%667.5K after |